Association Between Incident Type 2 Diabetes and Opium Use: Mediation by Body Mass and Adiposity

Overview

Journal Am J Epidemiol

Publisher Oxford University Press

Specialty Public Health

Date 2023 Aug 8

PMID 37552966

Authors

Mahdi Nalini

Hossein Poustchi

Gholamreza Roshandel

Farin Kamangar

Masoud Khoshnia

Abdolsamad Gharavi

Paul Brennan

Paolo Boffetta

Sanford M Dawsey

Christian C Abnet

Reza Malekzadeh

Arash Etemadi

Affiliations

Soon will be listed here.

Abstract

Opiates can affect glucose metabolism and obesity, but no large prospective study (to our knowledge) has investigated the association between long-term opium use, body mass index (BMI; weight (kg)/height (m)2), and incident type 2 diabetes mellitus (T2DM). We analyzed prospective data from 50,045 Golestan Cohort Study participants in Iran (enrollment: 2004-2008). After excluding participants with preexisting diseases, including diabetes, we used adjusted Poisson regression models to estimate incidence rate ratios (IRRs) and 95% confidence intervals (CIs) for T2DM in opium users compared with nonusers, using mediation analysis to assess the BMI-mediated association of opium use with incident T2DM. Of 40,083 included participants (mean age = 51.4 (standard deviation, 8.8) years; 56% female), 16% were opium users (median duration of use, 10 (interquartile range), 4-20) years). During follow-up (until January 2020), 5,342 incident T2DM cases were recorded, including 8.5% of opium users and 14.2% of nonusers. Opium use was associated with an overall decrease in incident T2DM (IRR = 0.83, 95% CI: 0.75, 0.92), with a significant dose-response association. Most (84.3%) of this association was mediated by low BMI or waist circumference, and opium use did not have a direct association with incident T2DM (IRR = 0.97, 95% CI: 0.87, 1.08). Long-term opium use was associated with lower incidence of T2DM, which was mediated by low body mass and adiposity.

References

Najafipour H, Sanjari M, Shokoohi M, Haghdoost A, Afshari M, Shadkam M . Epidemiology of diabetes mellitus, pre-diabetes, undiagnosed and uncontrolled diabetes and its predictors in general population aged 15 to 75 years: A community-based study (KERCADRS) in southeastern Iran. J Diabetes. 2014; 7(5):613-21. DOI: 10.1111/1753-0407.12195. View

Volkow N, Wise R . How can drug addiction help us understand obesity?. Nat Neurosci. 2005; 8(5):555-60. DOI: 10.1038/nn1452. View

Afshin A, Forouzanfar M, Reitsma M, Sur P, Estep K, Lee A . Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017; 377(1):13-27. PMC: 5477817. DOI: 10.1056/NEJMoa1614362. View

Masoudkabir F, Yavari N, Pashang M, Sadeghian S, Jalali A, Poorhosseini H . Effect of persistent opium consumption after surgery on the long-term outcomes of surgical revascularisation. Eur J Prev Cardiol. 2020; 27(18):1996-2003. DOI: 10.1177/2047487320932010. View

Kalant H . Opium revisited: a brief review of its nature, composition, non-medical use and relative risks. Addiction. 1997; 92(3):267-77. View

Cami J, Farre M . Drug addiction. N Engl J Med. 2003; 349(10):975-86. DOI: 10.1056/NEJMra023160. View

Stokes A, Lundberg D, Hempstead K, Berry K, Baker J, Preston S . Obesity and Incident Prescription Opioid Use in the U.S., 2000-2015. Am J Prev Med. 2020; 58(6):766-775. DOI: 10.1016/j.amepre.2019.12.018. View

. Carcinogenicity of opium consumption. Lancet Oncol. 2020; 21(11):1407-1408. DOI: 10.1016/S1470-2045(20)30611-2. View

Mohebbi E, Kamangar F, Rahimi-Movaghar A, Haghdoost A, Etemadi A, Amirzadeh S . An Exploratory Study of Units of Reporting Opium Usein Iran: Implications for Epidemiologic Studies. Arch Iran Med. 2019; 22(10):541-545. View

10.

Billes S, Sinnayah P, Cowley M . Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014; 84:1-11. DOI: 10.1016/j.phrs.2014.04.004. View

11.

Giugliano D, Torella R, Lefebvre P, DOnofrio F . Opioid peptides and metabolic regulation. Diabetologia. 1988; 31(1):3-15. DOI: 10.1007/BF00279126. View

12.

Islami F, Kamangar F, Nasrollahzadeh D, Aghcheli K, Sotoudeh M, Abedi-Ardekani B . Socio-economic status and oesophageal cancer: results from a population-based case-control study in a high-risk area. Int J Epidemiol. 2009; 38(4):978-88. PMC: 2720396. DOI: 10.1093/ije/dyp195. View

13.

Giugliano D, Ceriello A, Quatraro A, DOnofrio F . Endogenous opiates, heroin addiction, and non-insulin-dependent diabetes. Lancet. 1985; 2(8458):769-70. DOI: 10.1016/s0140-6736(85)90641-5. View

14.

Azod L, Rashidi M, Afkhami-Ardekani M, Kiani G, Khoshkam F . Effect of opium addiction on diabetes. Am J Drug Alcohol Abuse. 2008; 34(4):383-8. DOI: 10.1080/00952990802122580. View

15.

Hu L, Matthews A, Shmueli-Blumberg D, Killeen T, Tai B, VanVeldhuisen P . Prevalence of obesity for opioid- and stimulant-dependent participants in substance use treatment clinical trials. Drug Alcohol Depend. 2018; 190:255-262. DOI: 10.1016/j.drugalcdep.2018.06.014. View

16.

Khademi H, Kamangar F, Brennan P, Malekzadeh R . Opioid Therapy and its Side Effects: A Review. Arch Iran Med. 2016; 19(12):870-876. DOI: 0161912/AIM.0010. View

17.

Najafipour H, Beik A . The Impact of Opium Consumption on Blood Glucose, Serum Lipids and Blood Pressure, and Related Mechanisms. Front Physiol. 2016; 7:436. PMC: 5061814. DOI: 10.3389/fphys.2016.00436. View

18.

Dewan K, Dewan K, Idrees J, Navale S, Rosinski B, Svensson L . Trends and Outcomes of Cardiovascular Surgery in Patients With Opioid Use Disorders. JAMA Surg. 2018; 154(3):232-240. PMC: 6439637. DOI: 10.1001/jamasurg.2018.4608. View

19.

Hossain P, Kawar B, El Nahas M . Obesity and diabetes in the developing world--a growing challenge. N Engl J Med. 2007; 356(3):213-5. DOI: 10.1056/NEJMp068177. View

20.

Pop-Busui R, Boulton A, Feldman E, Bril V, Freeman R, Malik R . Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2016; 40(1):136-154. PMC: 6977405. DOI: 10.2337/dc16-2042. View